XNASOPRX
Market cap98mUSD
Jan 10, Last price
5.36USD
1D
-0.92%
1Q
-19.16%
Jan 2017
120.58%
IPO
32.35%
Name
OPTIMIZERx Corp
Chart & Performance
Profile
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 71,522 14.53% | 62,450 1.89% | |||||||
Cost of revenue | 82,342 | 72,719 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (10,820) | (10,269) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (7,598) | (852) | |||||||
Tax Rate | |||||||||
NOPAT | (3,222) | (9,416) | |||||||
Net income | (17,566) 65.93% | (10,586) -3,964.56% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (7,800) | 70,651,512 | |||||||
BB yield | 3.18% | -23,647.37% | |||||||
Debt | |||||||||
Debt current | 2,222 | 90 | |||||||
Long-term debt | 35,195 | 379 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 23,564 | (73,672) | |||||||
Cash flow | |||||||||
Cash from operating activities | (7,239) | 10,654 | |||||||
CAPEX | (87) | (245) | |||||||
Cash from investing activities | (25,337) | (58,176) | |||||||
Cash from financing activities | 28,220 | (18,951) | |||||||
FCF | (11,856) | (4,293) | |||||||
Balance | |||||||||
Cash | 13,852 | 74,141 | |||||||
Long term investments | |||||||||
Excess cash | 10,276 | 71,018 | |||||||
Stockholders' equity | (64,238) | (46,674) | |||||||
Invested Capital | 227,615 | 173,019 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 17,125 | 17,784 | |||||||
Price | 14.31 -14.82% | 16.80 -72.95% | |||||||
Market cap | 245,056 -17.98% | 298,771 -72.81% | |||||||
EV | 268,620 | 225,099 | |||||||
EBITDA | (8,419) | (8,247) | |||||||
EV/EBITDA | |||||||||
Interest | 1,454 | 852 | |||||||
Interest/NOPBT |